<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39012668</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2152-5250</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>Aging and disease</Title><ISOAbbreviation>Aging Dis</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 S Protein Reduces Cytoprotective Defenses and Promotes Human Endothelial Cell Senescence.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.14336/AD.2024.0405</ELocationID><Abstract><AbstractText>Premature vascular aging and endothelial cell senescence are major risk factors for cardiovascular diseases and atherothrombotic disturbances, which are main complications of both acute and long COVID-19. The S protein of SARS-CoV2, which acts as the receptor binding protein for the viral infection, is able to induce endothelial cells inflammation and it has been found as an isolated element in the circulation and in human tissues reservoirs months after infection. Here, we investigated whether the S protein is able to directly induce endothelial cell senescence and deciphered some of the mechanisms involved. In primary cultures of human umbilical vein endothelial cells (HUVEC), SARS-CoV-2 S protein enhanced in a concentration-dependent manner the cellular content of senescence and DNA damage response markers (senescence-associated-&#x3b2; galactosidase, &#x3b3;H2AX), as well as growth-arrest effectors (p53, p21, p16). In parallel, the S protein reduced the availability of cytoprotective proteins, such as the anti-aging protein klotho, Nrf2 or heme oxygenase-1, and caused functional harm by impairing ex vivo endothelial-dependent vasorelaxation in murine microvessels. These effects were prevented by the pharmacological inhibition of the NLRP3 inflammasome with MCC950. Furthermore, the supplementation with either recombinant klotho or angiotensin-(1-7), equally protected against the pro-senescence, pro-inflammatory and pro-oxidant action of the S protein. Globally, this study proposes novel mechanisms of disease in the context of COVID-19 and its vascular sequelae and provides pharmacological clues in order to prevent such complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Villacampa</LastName><ForeName>Alicia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vascular Pharmacology and Metabolism (FARMAVASM) group, IdiPAZ, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shamoon</LastName><ForeName>Licia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vascular Pharmacology and Metabolism (FARMAVASM) group, IdiPAZ, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valencia</LastName><ForeName>In&#xe9;s</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Molecular Neuroinflammation and Neuronal Plasticity Research Laboratory, Hospital Universitario Santa Cristina, IIS Hospital Universitario de La Princesa, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueiras</LastName><ForeName>Sof&#xed;a</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Cuesta</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vascular Pharmacology and Metabolism (FARMAVASM) group, IdiPAZ, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Ni&#xf1;o</LastName><ForeName>Dolores</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nephrology and Hypertension Lab, IIS-Fundaci&#xf3;n Jimenez Diaz, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;az-Araya</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pharmacological &amp;;amp Toxicological Chemistry, Faculty of Chemical &amp;;amp Pharmaceutical Sciences &amp;;amp Faculty of Medicine, University of Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-P&#xe9;rez</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaciones Biom&#xe9;dicas "Sols-Morreale" IIBM-CSIC-UAM, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomarkers and Personalized Approach to Cancer (BioPAC) Group. Area 3 Cancer -Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research Networking Centre on Rare Diseases, CIBERER, ISCIII, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorenzo</LastName><ForeName>&#xd3;scar</ForeName><Initials>&#xd3;</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Diabetes and Vascular pathology, IIS-Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research Networking Centre on Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Ferrer</LastName><ForeName>Carlos F&#xe9;lix</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vascular Pharmacology and Metabolism (FARMAVASM) group, IdiPAZ, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peir&#xf3;</LastName><ForeName>Concepci&#xf3;n</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vascular Pharmacology and Metabolism (FARMAVASM) group, IdiPAZ, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Aging Dis</MedlineTA><NlmUniqueID>101540533</NlmUniqueID><ISSNLinking>2152-5250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>16</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>16</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>16</Day><Hour>11</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39012668</ArticleId><ArticleId IdType="doi">10.14336/AD.2024.0405</ArticleId><ArticleId IdType="pii">AD.2024.0405</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>